{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:35:39Z","timestamp":1776861339323,"version":"3.51.2"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40256-025-00777-2","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:26:37Z","timestamp":1763382397000},"page":"269-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly"],"prefix":"10.1007","volume":"26","author":[{"given":"Rosana G.","family":"Bianchettin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Lopez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5349-8234","authenticated-orcid":false,"given":"Marie-Eve","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"777_CR1","unstructured":"World Health Organization. Cardiovascular diseases. Cardiovascular diseases (CVDs). [Online]. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed 31 Mar 2025."},{"issue":"20","key":"777_CR2","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/cir.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606\u201335. https:\/\/doi.org\/10.1161\/cir.0000000000001184.","journal-title":"Circulation"},{"issue":"4","key":"777_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1177\/1479164110383723","volume":"7","author":"SH Alzahrani","year":"2010","unstructured":"Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res. 2010;7(4):260\u201373. https:\/\/doi.org\/10.1177\/1479164110383723.","journal-title":"Diab Vasc Dis Res"},{"issue":"6","key":"777_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22063170","volume":"22","author":"R Altalhi","year":"2021","unstructured":"Altalhi R, Pechlivani N, Ajjan RA. PAI-1 in diabetes: pathophysiology and role as a therapeutic target. Int J Mol Sci. 2021;22(6):3170. https:\/\/doi.org\/10.3390\/IJMS22063170.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"777_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jacc.2009.07.029","volume":"55","author":"TB Horwich","year":"2010","unstructured":"Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes: relevance to incidence of heart failure. J Am Coll Cardiol. 2010;55(4):283\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"777_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/eurheartj\/ehp396","volume":"31","author":"SA Cook","year":"2010","unstructured":"Cook SA, et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J. 2010;31(1):100\u201311.","journal-title":"Eur Heart J"},{"key":"777_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.570421","volume":"11","author":"AA Greenwell","year":"2020","unstructured":"Greenwell AA, Gopal K, Ussher JR. Myocardial energy metabolism in non-ischemic cardiomyopathy. Front Physiol. 2020;11:570421. https:\/\/doi.org\/10.3389\/fphys.2020.570421.","journal-title":"Front Physiol"},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.plefa.2016.06.002","volume":"136","author":"Y Liu","year":"2018","unstructured":"Liu Y, Neumann D, Glatz JFC, Luiken J. Molecular mechanism of lipid-induced cardiac insulin resistance and contractile dysfunction. Prostaglandins Leukot Essent Fatty Acids. 2018;136:131\u201341. https:\/\/doi.org\/10.1016\/j.plefa.2016.06.002.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"7","key":"777_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165775","volume":"1866","author":"J Luiken","year":"2020","unstructured":"Luiken J, Nabben M, Neumann D, Glatz JFC. Understanding the distinct subcellular trafficking of CD36 and GLUT4 during the development of myocardial insulin resistance. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165775. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165775.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"10","key":"777_CR10","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/j.bbalip.2016.02.011","volume":"1861","author":"I Zlobine","year":"2016","unstructured":"Zlobine I, Gopal K, Ussher JR. Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochim Biophys Acta. 2016;1861(10):1555\u201368. https:\/\/doi.org\/10.1016\/j.bbalip.2016.02.011.","journal-title":"Biochim Biophys Acta"},{"key":"777_CR11","doi-asserted-by":"publisher","unstructured":"EA-AJ of Physiology-Endocrinology and undefined 2021. Insulin signaling in the heart. journals.physiology.org. 2021;321(1):130\u2013145. https:\/\/doi.org\/10.1152\/ajpendo.00158.2021.","DOI":"10.1152\/ajpendo.00158.2021"},{"issue":"2","key":"777_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurjhf\/hfn043","volume":"11","author":"S Heymans","year":"2009","unstructured":"Heymans S, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11(2):119\u201329.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"777_CR13","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1586\/erc.09.31","volume":"7","author":"JH Karnes","year":"2009","unstructured":"Karnes JH, Cooper-DeHoff RM. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther. 2009;7(6):689\u2013702. https:\/\/doi.org\/10.1586\/erc.09.31.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"777_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000125","author":"RM Cooper-DeHoff","year":"2013","unstructured":"Cooper-DeHoff RM, Bird ST, Nichols GA, Delaney JA, Winterstein AG. Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study. J Am Heart Assoc. 2013. https:\/\/doi.org\/10.1161\/JAHA.113.000125.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"777_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/HYPERTENSIONAHA.109.139592","volume":"55","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, et al. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010;55(1):61\u20138.","journal-title":"Hypertension"},{"issue":"5","key":"777_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/J.JACC.2019.04.067","volume":"74","author":"P Joseph","year":"2019","unstructured":"Joseph P, Swedberg K, Leong DP, Yusuf S. The evolution of \u03b2-blockers in coronary artery disease and heart failure (Part 1\/5). J Am Coll Cardiol. 2019;74(5):672\u201382. https:\/\/doi.org\/10.1016\/J.JACC.2019.04.067.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"777_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/1573402114666180918102735","volume":"15","author":"GT do Vale","year":"2019","unstructured":"do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of \u03b2-blockers: history, class differences and clinical applicability. Curr Hypertens Rev. 2019;15(1):22\u201331. https:\/\/doi.org\/10.2174\/1573402114666180918102735.","journal-title":"Curr Hypertens Rev"},{"issue":"2","key":"777_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.hyp.37.2.250","volume":"37","author":"AM Sharma","year":"2001","unstructured":"Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37(2):250\u20134. https:\/\/doi.org\/10.1161\/01.hyp.37.2.250.","journal-title":"Hypertension"},{"issue":"13","key":"777_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200003303421301","volume":"342","author":"TW Gress","year":"2000","unstructured":"Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342(13):905\u201312. https:\/\/doi.org\/10.1056\/NEJM200003303421301.","journal-title":"N Engl J Med"},{"key":"777_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5767306","volume":"2021","author":"MA Gammone","year":"2021","unstructured":"Gammone MA, Efthymakis K, D\u2019Orazio N. Effect of third-generation beta blockers on weight loss in a population of overweight-obese subjects in a controlled dietary regimen. J Nutr Metab. 2021;2021:1\u20137.","journal-title":"J Nutr Metab"},{"issue":"4","key":"777_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/HJH.0b013e3280127948","volume":"25","author":"P Dandona","year":"2007","unstructured":"Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25(4):731\u201341.","journal-title":"J Hypertens"},{"key":"777_CR22","doi-asserted-by":"crossref","unstructured":"Bakris GL et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227\u20132236. [Online]. Available: https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/199763\/joc42136.pdf.","DOI":"10.1001\/jama.292.21.2583"},{"key":"777_CR23","first-page":"1","volume":"3","author":"Y Sirenko","year":"2017","unstructured":"Sirenko Y, Rekovets O, Torbas O, Savitskiy S, Pavlyuk E. Effect of beta-blockers on insulin resistance in patients with hypertension and metabolic syndrome after 6 months of treatment. J Endocrinol Diab. 2017;3:1\u201311.","journal-title":"J Endocrinol Diab"},{"issue":"3","key":"777_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01.hjh.0000209993.26057.de","volume":"24","author":"T Celik","year":"2006","unstructured":"Celik T, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24(3):591\u20136.","journal-title":"J Hypertens"},{"issue":"1","key":"777_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/1074248416644987","volume":"22","author":"AG Ozy\u0131ld\u0131z","year":"2017","unstructured":"Ozy\u0131ld\u0131z AG, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H. Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther. 2017;22(1):65\u201370.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"777_CR26","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2165\/00044011-200727120-00006","volume":"27","author":"AC Schmidt","year":"2007","unstructured":"Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin Drug Investig. 2007;27:841\u20139.","journal-title":"Clin Drug Investig"},{"key":"777_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02682-w","author":"R Wang","year":"2022","unstructured":"Wang R, et al. Effect of sacubitril\/valsartan and ACEI\/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials. BMC Med. 2022. https:\/\/doi.org\/10.1186\/s12916-022-02682-w.","journal-title":"BMC Med"},{"issue":"10313","key":"777_CR28","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/s0140-6736(21)01920-6","volume":"398","author":"M Nazarzadeh","year":"2021","unstructured":"Nazarzadeh M, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398(10313):1803\u201310. https:\/\/doi.org\/10.1016\/s0140-6736(21)01920-6.","journal-title":"Lancet"},{"issue":"9","key":"777_CR29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1161\/CIRCULATIONAHA.105.548461","volume":"112","author":"H-TS Investigators","year":"2005","unstructured":"Investigators H-TS. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation. 2005;112(9):1339\u201346.","journal-title":"Circulation"},{"issue":"9","key":"777_CR30","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","volume":"107","author":"E Vermes","year":"2003","unstructured":"Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the studies of left ventricular dysfunction (SOLVD). Circulation. 2003;107(9):1291\u20136.","journal-title":"Circulation"},{"key":"777_CR31","doi-asserted-by":"crossref","unstructured":"Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004;363(9426):2022\u20132031. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673604164519?via%3Dihub.","DOI":"10.1016\/S0140-6736(04)16451-9"},{"key":"777_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/dmso.S49767","volume":"6","author":"H Noto","year":"2013","unstructured":"Noto H, Goto A, Tsujimoto T, Noda M. Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes. 2013;6:257\u201361. https:\/\/doi.org\/10.2147\/dmso.S49767.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"777_CR33","doi-asserted-by":"crossref","unstructured":"Li J-C, Cheng P-C, Huang C-N, Jian L-F, Wu Y-S, Lin C-L. Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study. Front Endocrinol (Lausanne). 2022;p. 2184.","DOI":"10.3389\/fendo.2022.935561"},{"issue":"21","key":"777_CR34","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","volume":"290","author":"CJ Pepine","year":"2003","unstructured":"Pepine CJ, et al. A calcium antagonist vs a non\u2013calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805\u201316.","journal-title":"JAMA"},{"issue":"4","key":"777_CR35","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2337\/db11-0955","volume":"61","author":"G Xu","year":"2012","unstructured":"Xu G, Chen J, Jing G, Shalev A. Preventing \u03b2-cell loss and diabetes with calcium channel blockers. Diabetes. 2012;61(4):848\u201356. https:\/\/doi.org\/10.2337\/db11-0955.","journal-title":"Diabetes"},{"key":"777_CR36","doi-asserted-by":"crossref","unstructured":"Barzilay JI et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006;166(20):2191\u20132201. [Online]. Available: https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/411240\/ioi60123_2191_2201.pdf.","DOI":"10.1001\/archinte.166.20.2191"},{"issue":"1","key":"777_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjcard.2004.08.059","volume":"95","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29\u201335.","journal-title":"Am J Cardiol"},{"key":"777_CR38","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s11606-020-05731-3","volume":"35","author":"JJ Hall","year":"2020","unstructured":"Hall JJ, Eurich DT, Nagy D, Tjosvold L, Gamble J-M. Thiazide diuretic\u2013induced change in fasting plasma glucose: a meta-analysis of randomized clinical trials. J Gen Intern Med. 2020;35:1849\u201360.","journal-title":"J Gen Intern Med"},{"key":"777_CR39","doi-asserted-by":"crossref","unstructured":"Zhang X, Zhao Q. Association of thiazide\u2010type diuretics with glycemic changes in hypertensive patients: a systematic review and meta\u2010analysis of randomized controlled clinical trials. J Clin Hypertens. 2016;18(4):342\u2013351. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8031670\/pdf\/JCH-18-342.pdf.","DOI":"10.1111\/jch.12679"},{"issue":"2","key":"777_CR40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","volume":"48","author":"AJ Zillich","year":"2006","unstructured":"Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006;48(2):219\u201324.","journal-title":"Hypertension"},{"issue":"2","key":"777_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1161\/CIRCOUTCOMES.111.962522","volume":"5","author":"JI Barzilay","year":"2012","unstructured":"Barzilay JI, et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT diabetes extension study. Circ Cardiovasc Qual Outcomes. 2012;5(2):153\u201362.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"19","key":"777_CR42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.jacc.2017.11.005","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):2199\u2013269. https:\/\/doi.org\/10.1016\/j.jacc.2017.11.005.","journal-title":"J Am Coll Cardiol"},{"key":"777_CR43","unstructured":"Garber AJ et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20132020 executive summary. Endocr Pract. 2020;26(1): 107\u2013139. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1530891X20350667?via%3Dihub."},{"issue":"4","key":"777_CR44","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"5","key":"777_CR45","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2337\/dc08-1709","volume":"32","author":"D Preiss","year":"2009","unstructured":"Preiss D, et al. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care. 2009;32(5):915\u201320.","journal-title":"Diabetes Care"},{"issue":"10","key":"777_CR46","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","volume":"47","author":"JI Davies","year":"2004","unstructured":"Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47(10):1687\u201394. https:\/\/doi.org\/10.1007\/s00125-004-1510-8.","journal-title":"Diabetologia"},{"issue":"5","key":"777_CR47","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","volume":"51","author":"K Swaminathan","year":"2008","unstructured":"Swaminathan K, Davies J, George J, Rajendra NS, Morris AD, Struthers AD. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia. 2008;51(5):762\u20138. https:\/\/doi.org\/10.1007\/s00125-008-0972-5.","journal-title":"Diabetologia"},{"issue":"4","key":"777_CR48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","volume":"46","author":"H Ando","year":"2023","unstructured":"Ando H. Inhibition of aldosterone synthase: does this offer advantages compared with the blockade of mineralocorticoid receptors? Hypertens Res. 2023;46(4):1056\u20137. https:\/\/doi.org\/10.1038\/s41440-023-01188-z.","journal-title":"Hypertens Res"},{"issue":"15","key":"777_CR49","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14971","volume":"9","author":"SH Finsen","year":"2021","unstructured":"Finsen SH, Hansen MR, Hoffmann-Petersen J, H\u00f8jgaard HF, Mortensen SP. Eight weeks of mineralocorticoid blockade does not improve insulin sensitivity in type 2 diabetes. Physiol Rep. 2021;9(15):e14971. https:\/\/doi.org\/10.14814\/phy2.14971.","journal-title":"Physiol Rep"},{"issue":"8","key":"777_CR50","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","volume":"14","author":"D Preiss","year":"2012","unstructured":"Preiss D, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2012;14(8):909\u201315.","journal-title":"Eur J Heart Fail"},{"key":"777_CR51","doi-asserted-by":"publisher","unstructured":"Kobalava Z et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ 696) in patients with heart failure and reduced ejection fraction. Wiley Online LibraryZ Kobalava, Y Kotovskaya, O Averkov, E Pavlikova, V Moiseev, D Albrecht, P ChandraCardiovascular therapeutics, 2016\u2022Wiley Online Library, 2016; vol. 34, no. 4, pp. 191\u2013198. https:\/\/doi.org\/10.1111\/1755-5922.12183.","DOI":"10.1111\/1755-5922.12183"},{"key":"777_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2022.897109\/BIBTEX","volume":"13","author":"G Armentaro","year":"2022","unstructured":"Armentaro G, et al. Long Term Metabolic Effects of Sacubitril\/Valsartan in Non-Diabetic and Diabetic Patients With Heart Failure Reduced Ejection Fraction: A Real Life Study. Front Physiol. 2022;13:897109. https:\/\/doi.org\/10.3389\/FPHYS.2022.897109\/BIBTEX.","journal-title":"Front Physiol"},{"issue":"5","key":"777_CR53","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","volume":"5","author":"JP Seferovic","year":"2017","unstructured":"Seferovic JP, et al. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333\u201340. https:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"777_CR54","doi-asserted-by":"publisher","unstructured":"Selvaraj S et al. Effects of sacubitril\/valsartan on serum lipids in heart failure with preserved ejection fraction. ahajournals.orgS Selvaraj, BL Claggett, M Packer, F Zannad, IS Anand, B Pieske, Z Zhao, VC ShiJournal of the American Heart Association, 2021\u2022ahajournals.org, vol. 10, no. 17, p. 22069, Sep. 2021, https:\/\/doi.org\/10.1161\/JAHA.121.022069.","DOI":"10.1161\/JAHA.121.022069"},{"key":"777_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.940654\/FULL","author":"C Cloro","year":"2022","unstructured":"Cloro C, et al. Effects of sacubitril\/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction. Front Endocrinol (Lausanne). 2022. https:\/\/doi.org\/10.3389\/FENDO.2022.940654\/FULL.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"777_CR56","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/CPT.455","volume":"101","author":"J Jordan","year":"2017","unstructured":"Jordan J, et al. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254\u201363. https:\/\/doi.org\/10.1002\/CPT.455.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"777_CR57","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.116.003196","volume":"5","author":"E Rayner-Hartley","year":"2016","unstructured":"Rayner-Hartley E, Sedlak T. Ranolazine: a contemporary review. J Am Heart Assoc. 2016;5(3):e003196. https:\/\/doi.org\/10.1161\/jaha.116.003196.","journal-title":"J Am Heart Assoc"},{"key":"777_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010031","author":"S Rouhana","year":"2021","unstructured":"Rouhana S, Virsolvy A, Fares N, Richard S, Thireau J. Ranolazine: an old drug with emerging potential; lessons from pre-clinical and clinical investigations for possible repositioning. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph15010031.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"777_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2337\/dc14-2629","volume":"38","author":"RH Eckel","year":"2015","unstructured":"Eckel RH, et al. Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015;38(7):1189\u201396. https:\/\/doi.org\/10.2337\/dc14-2629.","journal-title":"Diabetes Care"},{"issue":"3","key":"777_CR60","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309\u201316.","journal-title":"JAMA"},{"issue":"1","key":"777_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","volume":"27","author":"AD Timmis","year":"2006","unstructured":"Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006;27(1):42\u20138.","journal-title":"Eur Heart J"},{"key":"777_CR62","unstructured":"Yang M, Chu R, Belardinelli L, Dhalla A. Inhibition of glucagon secretion in rat pancreatic islets via Na+ channels: mechanism of anti-diabetic effect of ranolazine. In: Diabetes, AMER DIABETES ASSOC 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA, 2013, pp. A234\u2013A234."},{"issue":"6","key":"777_CR63","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/MOL.0b013e32834b4994","volume":"22","author":"D Preiss","year":"2011","unstructured":"Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011;22(6):460\u20136.","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"777_CR64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","volume":"172","author":"AL Culver","year":"2012","unstructured":"Culver AL, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women\u2019s Health Initiative. Arch Intern Med. 2012;172(2):144\u201352.","journal-title":"Arch Intern Med"},{"issue":"9965","key":"777_CR65","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0140-6736(14)61183-1","volume":"385","author":"DI Swerdlow","year":"2015","unstructured":"Swerdlow DI, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(14)61183-1.","journal-title":"Lancet"},{"issue":"5","key":"777_CR66","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","volume":"58","author":"H Cederberg","year":"2015","unstructured":"Cederberg H, Stan\u010d\u00e1kov\u00e1 A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5):1109\u201317. https:\/\/doi.org\/10.1007\/s00125-015-3528-5.","journal-title":"Diabetologia"},{"key":"777_CR67","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2610","volume":"346","author":"AA Carter","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. https:\/\/doi.org\/10.1136\/bmj.f2610.","journal-title":"BMJ"},{"issue":"9841","key":"777_CR68","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/s0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(12)61190-8.","journal-title":"Lancet"},{"issue":"9716","key":"777_CR69","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342.","journal-title":"Lancet"},{"key":"777_CR70","doi-asserted-by":"publisher","first-page":"39982","DOI":"10.1038\/srep39982","volume":"7","author":"S Wang","year":"2017","unstructured":"Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Sci Rep. 2017;7:39982. https:\/\/doi.org\/10.1038\/srep39982.","journal-title":"Sci Rep"},{"key":"777_CR71","unstructured":"Reith C, Preiss D, Blackwell L, \u2026 J. E.-T. L. D. &, and undefined 2024. \u201cEffects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data,\u201d thelancet.comC Reith, D Preiss, L Blackwell, J Emberson, E Spata, K Davies, H Halls, C Harper, L HollandThe Lancet Diabetes & Endocrinology, 2024\u2022thelancet.com. [Online]. Available: https:\/\/www.thelancet.com\/journals\/landia\/article\/PIIS2213-8587(24)00040-8\/fulltext. Accessed 1 Apr 2025."},{"key":"777_CR72","doi-asserted-by":"crossref","unstructured":"Vallejo-Vaz A, Seshasai S, Kurogi K, IM-Atherosclerosis, and undefined 2015. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Elsevier. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0021915015013519. Accessed 1 Apr 2025.","DOI":"10.1016\/j.atherosclerosis.2015.06.001"},{"issue":"7","key":"777_CR73","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.118.011581","volume":"8","author":"SU Khan","year":"2019","unstructured":"Khan SU, et al. Association of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering therapies and risk of diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8(7):e011581. https:\/\/doi.org\/10.1161\/jaha.118.011581.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"777_CR74","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Inclisiran: first approval. Drugs. 2021;81(3):389\u201395. https:\/\/doi.org\/10.1007\/s40265-021-01473-6.","journal-title":"Drugs"},{"issue":"10349","key":"777_CR75","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"B-K Kim","year":"2022","unstructured":"Kim B-K, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00916-3.","journal-title":"Lancet"},{"key":"777_CR76","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.029593","author":"NP Shah","year":"2023","unstructured":"Shah NP, et al. Impact of ezetimibe on new-onset diabetes: a substudy of IMPROVE-IT. J Am Heart Assoc. 2023. https:\/\/doi.org\/10.1161\/jaha.122.029593.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"777_CR77","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40256-021-00516-3","volume":"22","author":"KH Shin","year":"2022","unstructured":"Shin KH, Choi HD. Comparison of efficacy and safety of statin-ezetimibe combination therapy with statatin monotherapy in patients with diabetes: a meta-analysis of randomized controlled studies. Am J Cardiovasc Drugs. 2022;22(4):395\u2013406. https:\/\/doi.org\/10.1007\/s40256-021-00516-3.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"777_CR78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.diabres.2012.12.026","volume":"100","author":"T Tsunoda","year":"2013","unstructured":"Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100(1):46\u201352. https:\/\/doi.org\/10.1016\/j.diabres.2012.12.026.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"777_CR79","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/fcp.12406","volume":"33","author":"F Montastruc","year":"2019","unstructured":"Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase(\u00ae). Fundam Clin Pharmacol. 2019;33(1):108\u201312. https:\/\/doi.org\/10.1111\/fcp.12406.","journal-title":"Fundam Clin Pharmacol"},{"key":"777_CR80","doi-asserted-by":"crossref","unstructured":"Simental-Mendia L,\u2026 M. S.-M.-P., and undefined 2018. Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials. ElsevierLE Simental-Mendia, M Simental-Mendia, A Sanchez-Garcia, M Banach, SL AtkinPharmacological research, 2018\u2022Elsevier, [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1043661817316158. Accessed 1 Apr 2025.","DOI":"10.1111\/DOM.16506\/v2\/response1"},{"key":"777_CR81","unstructured":"FSI-T Lancet and undefined 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Elsevier. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673605676672. Accessed 1 Apr 2025."},{"key":"777_CR82","unstructured":"JBuse J, A. S. G.-T. A. journal of cardiology, and undefined 2007. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. ElsevierJB Buse, ACCORD Study GroupThe American journal of cardiology, 2007\u2022Elsevier. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002914907004389. Accessed 1 Apr 2025."},{"issue":"1","key":"777_CR83","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-021-01291-w","volume":"20","author":"K Yokote","year":"2021","unstructured":"Yokote K, et al. Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials. Cardiovasc Diabetol. 2021;20(1):96. https:\/\/doi.org\/10.1186\/s12933-021-01291-w.","journal-title":"Cardiovasc Diabetol"},{"key":"777_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071838","author":"H Nomoto","year":"2023","unstructured":"Nomoto H, et al. Favorable effect of pemafibrate on insulin resistance and \u03b2-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15071838.","journal-title":"Pharmaceutics"},{"issue":"21","key":"777_CR85","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMOA2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan A, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022;387(21):1923\u201334. https:\/\/doi.org\/10.1056\/NEJMOA2210645.","journal-title":"N Engl J Med"},{"key":"777_CR86","doi-asserted-by":"publisher","unstructured":"Wilson PWF et al. Systematic review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report. ahajournals.org, 2019;139(25): 1144\u20131161. https:\/\/doi.org\/10.1161\/CIR.0000000000000626.","DOI":"10.1161\/CIR.0000000000000626"},{"issue":"5","key":"777_CR87","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1161\/circulationaha.111.018259","volume":"124","author":"PJ Barter","year":"2011","unstructured":"Barter PJ, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation. 2011;124(5):555\u201362. https:\/\/doi.org\/10.1161\/circulationaha.111.018259.","journal-title":"Circulation"},{"issue":"6","key":"777_CR88","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","volume":"8","author":"K Dangas","year":"2022","unstructured":"Dangas K, Navar AM, Kastelein JJP. The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis. Eur Heart J. 2022;8(6):622\u201332. https:\/\/doi.org\/10.1093\/ehjcvp\/pvac025.","journal-title":"Eur Heart J"},{"key":"777_CR89","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1475-2840-12-100","volume":"12","author":"EA Brinton","year":"2013","unstructured":"Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study. Cardiovasc Diabetol. 2013;12:100. https:\/\/doi.org\/10.1186\/1475-2840-12-100.","journal-title":"Cardiovasc Diabetol"},{"key":"777_CR90","doi-asserted-by":"publisher","DOI":"10.2337\/db20-4-LB","author":"DL Bhatt","year":"2020","unstructured":"Bhatt DL, et al. 4-LB: Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: reduce-it diabetes. Diabetes. 2020. https:\/\/doi.org\/10.2337\/db20-4-LB.","journal-title":"Diabetes"},{"key":"777_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjopen\/oead115","volume":"380","author":"M Miller","year":"2019","unstructured":"Miller M, Bhatt DL, Brinton EA, Jacobson TA, Steg PG, Pineda AL, et al. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn. Eur Heart J Open. 2019;380:1\u20139. https:\/\/doi.org\/10.1093\/ehjopen\/oead115.","journal-title":"Eur Heart J Open"},{"issue":"10","key":"777_CR92","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","volume":"24","author":"M Ruscica","year":"2022","unstructured":"Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and when. Curr Atheroscler Rep. 2022;24(10):791\u2013801. https:\/\/doi.org\/10.1007\/s11883-022-01054-2.","journal-title":"Curr Atheroscler Rep"},{"issue":"15","key":"777_CR93","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMOA2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364. https:\/\/doi.org\/10.1056\/NEJMOA2215024.","journal-title":"N Engl J Med"},{"key":"777_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00316-9","author":"KK Ray","year":"2024","unstructured":"Ray KK, Nicholls SJ, Li N, Louie MJ, Brennan D, Lincoff AM, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024. https:\/\/doi.org\/10.1016\/S2213-8587(23)00316-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"777_CR95","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"GD Lopaschuk","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. Basic to Translational Science. 2020;5(6):632\u201344.","journal-title":"Basic to Translational Science"},{"issue":"2","key":"777_CR96","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/JAMACARDIO.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358. https:\/\/doi.org\/10.1001\/JAMACARDIO.2020.4511.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"777_CR97","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1093\/ndt\/gfad112","volume":"38","author":"PB Mark","year":"2023","unstructured":"Mark PB, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38(11):2444\u201355. https:\/\/doi.org\/10.1093\/ndt\/gfad112.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"777_CR98","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u2018thrifty substrate\u2019 hypothesis. Diabetes Care. 2016;39(7):1108\u201314. https:\/\/doi.org\/10.2337\/dc16-0330.","journal-title":"Diabetes Care"},{"key":"777_CR99","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.2147\/jir.S331320","volume":"14","author":"S Liao","year":"2021","unstructured":"Liao S, et al. \u03b2-Hydroxybutyrate mitigated heart failure with preserved ejection fraction by increasing Treg cells via Nox2\/GSK-3\u03b2. J Inflamm Res. 2021;14:4697\u2013706. https:\/\/doi.org\/10.2147\/jir.S331320.","journal-title":"J Inflamm Res"},{"key":"777_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.09.009","volume":"132","author":"E Gronda","year":"2025","unstructured":"Gronda E, et al. Gliflozines use in heart failure patients. Focus on renal actions and overview of clinical experience. Eur J Intern Med. 2025;132:1\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2024.09.009.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"777_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMOA1504720","volume":"13","author":"S Steiner","year":"2016","unstructured":"Steiner S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Z Gefassmed. 2016;13(1):17\u20138. https:\/\/doi.org\/10.1056\/NEJMOA1504720.","journal-title":"Z Gefassmed"},{"key":"777_CR102","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, \u2026 K. M.-\u2026 E. J. of, and undefined 2017. Canagliflozin and cardiovascular and renal events in type 2 diabetes. Mass Med Soc. https:\/\/doi.org\/10.1056\/NEJMoa1611925. Accessed 1 Apr 2025.","DOI":"10.1056\/NEJMoa1611925"},{"issue":"24","key":"777_CR103","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMOA1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMOA1811744.","journal-title":"N Engl J Med"},{"issue":"4","key":"777_CR104","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMOA1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMOA1812389.","journal-title":"N Engl J Med"},{"issue":"S2","key":"777_CR105","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/dom.13630","volume":"21","author":"JA Dominguez Rieg","year":"2019","unstructured":"Dominguez Rieg JA, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: prospects for dual inhibition. Diabetes Obes Metab. 2019;21(S2):43\u201352. https:\/\/doi.org\/10.1111\/dom.13630.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"777_CR106","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMOA2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328. https:\/\/doi.org\/10.1056\/NEJMOA2030183.","journal-title":"N Engl J Med"},{"issue":"2","key":"777_CR107","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMOA2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339. https:\/\/doi.org\/10.1056\/NEJMOA2030186.","journal-title":"N Engl J Med"},{"issue":"8","key":"777_CR108","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2023.30754","volume":"6","author":"KY Chen","year":"2023","unstructured":"Chen KY, et al. Time to benefit of Sodium-glucose cotransporter-2 inhibitors among patients with heart failure. JAMA Netw Open. 2023;6(8):E2330754. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2023.30754.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"777_CR109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"M Nauck","year":"2021","unstructured":"Nauck M, Quast D, J. W.- Diabetes, O. and, and undefined 2021. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update. Wiley Online Libr. 2021;23(3):5\u201329. https:\/\/doi.org\/10.1111\/dom.14496.","journal-title":"Wiley Online Libr"},{"issue":"1","key":"777_CR110","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMOA2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336. https:\/\/doi.org\/10.1056\/NEJMOA2416394.","journal-title":"N Engl J Med"},{"key":"777_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/EDM2.70045","author":"J Wen","year":"2025","unstructured":"Wen J, et al. Tirzepatide versus semaglutide on weight loss in type 2 diabetes patients: a systematic review and meta-analysis of direct comparative studies. Endocrinol Diabetes Metab. 2025. https:\/\/doi.org\/10.1002\/EDM2.70045.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"6","key":"777_CR112","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMOA2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315. https:\/\/doi.org\/10.1056\/NEJMOA2107519.","journal-title":"N Engl J Med"},{"key":"777_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art. Mol Metab. 2021. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102.","journal-title":"Mol Metab"},{"key":"777_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/10742484221146371","volume":"27","author":"EM Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 EM, Vol\u010dan\u0161ek \u0160, Tom\u0161i\u0107 KZ, Jane\u017e A, Mikhailidis DP, Rizzo M, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists in the treatment of. J Cardiovasc Pharmacol Therap. 2022;27:1\u201322. https:\/\/doi.org\/10.1177\/10742484221146371.","journal-title":"J Cardiovasc Pharmacol Therap"},{"key":"777_CR115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"777_CR116","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMOA1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMOA1607141.","journal-title":"N Engl J Med"},{"issue":"9","key":"777_CR117","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMOA1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMOA1901118.","journal-title":"N Engl J Med"},{"key":"777_CR118","doi-asserted-by":"publisher","unstructured":"Lincoff A, \u2026 KB-F-\u2026 E. J. of, and undefined 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes. Mass Medical SocAM Lincoff, K Brown-Frandsen, HM Colhoun, J Deanfield, SS Emerson, S EsbjergNew England Journal of Medicine, 2023\u2022Mass Medical Soc. Accessed Apr. 01, 2025. [Online]. https:\/\/doi.org\/10.1056\/NEJMoa2307563. Accessed 1 Apr 2025.","DOI":"10.1056\/NEJMoa2307563"},{"issue":"10","key":"777_CR119","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/s2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385. https:\/\/doi.org\/10.1016\/s2213-8587(19)30249-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"777_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/ph14100991","author":"AS Bhagavathula","year":"2021","unstructured":"Bhagavathula AS, Vidyasagar K, Tesfaye W. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II\/III trials. Pharmaceuticals (Basel). 2021. https:\/\/doi.org\/10.3390\/ph14100991.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"777_CR121","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01707-4.","journal-title":"Nat Med"},{"issue":"2","key":"777_CR122","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/S12020-019-02175-6","volume":"67","author":"M Guo","year":"2020","unstructured":"Guo M, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine. 2020;67(2):294\u2013304. https:\/\/doi.org\/10.1007\/S12020-019-02175-6.","journal-title":"Endocrine"},{"issue":"17","key":"777_CR123","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation. 2019;139(17):2022\u201331. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038868.","journal-title":"Circulation"},{"key":"777_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-021-01281-Y","author":"O Mosenzon","year":"2021","unstructured":"Mosenzon O, et al. From glucose lowering agents to disease\/diabetes modifying drugs: a \u2018SIMPLE\u2019 approach for the treatment of type 2 diabetes. Cardiovasc Diabetol. 2021. https:\/\/doi.org\/10.1186\/S12933-021-01281-Y.","journal-title":"Cardiovasc Diabetol"},{"key":"777_CR125","doi-asserted-by":"publisher","DOI":"10.1007\/S13300-025-01726-7","author":"EB Stougaard","year":"2025","unstructured":"Stougaard EB, Curovic VR, Hansen TW. Combining SGLT2is, GLP1-RAs and nsMRAs in diabetes: a scoping review of current and future perspectives. Diabetes Ther. 2025. https:\/\/doi.org\/10.1007\/S13300-025-01726-7.","journal-title":"Diabetes Ther"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00777-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00777-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00777-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:36:50Z","timestamp":1776857810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00777-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00777-2","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rosana G. Bianchettin, Paul Poirier, Francisco Lopez Jimenez, Carl J. Lavie, and Marie-Eve Pich\u00e9 declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors contributed to writing and reviewing this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Data sharing not applicable to this manuscript as no datasets were generated for it.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}